EUVIMEDEUVIMED entdecken
Kohortenstudie

Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study

Li Wang iD, Lixin Wang, Zengzhen Wei, Chunyan Huang, Li Qin, Bin Tan

Pharmacoepidemiology and Drug Safety · 2026

DOI: 10.1002/pds.70259 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Li Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Medicine, Sichuan University West China Hospital, Chengdu, China. Hauptthemen laut MEDLINE: Anemia, Hemolytic, beta Lactam Antibiotics, Anti-Bacterial Agents, Antibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug‐induced immune hemolytic anemia (DIIHA), a rare complication of beta‐lactams, lacks population‐level data on subclinical antibody prevalence.

Objective

To quantify drug‐induced antibody incidence and hematologic impact in beta‐lactam‐treated patients.

Methods

Prospective cohort of 4040 patients receiving ceftriaxone, piperacillin/trizobactam, piperacillin/sulbactam 2:1 and piperacillin/tazobactam at a Chinese tertiary hospital (2020.1–2020.9). Antibodies were detected via immunoadsorption assays. The primary outcomes were changes in hemoglobin, bilirubin, and lactate dehydrogenase (LDH) levels.

Results

Antibody positivity occurred in 18.07% (730/4040), highest with piperacillin/sulbactam 2:1 (24.02% vs. 0.43% Ceftriaxone, p < 0.001). Seropositive patients had a significant hemoglobin decline (Δ = −5.00 g/L, 95% CI −6.2 to −3.8) and bilirubin elevation (Δ = +0.95 μmol/L, 95% CI +0.4 to +1.5), but only 0.2% (2/730) progressed to severe anemia. Subclinical hemolysis (LDH > 250 U/L) was prevalent (89.3%).

Conclusion

Beta‐lactams exhibit high asymptomatic antibody rates (18.07%) with minimal severe hemolysis risk (0.2%). Protocolized monitoring and HLA screening may optimize safety. This first large‐scale prospective cohort quantifies the underrecognized epidemic of subclinical antibody formation, challenging traditional pharmacovigilance frameworks that focus solely on overt hemolysis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolyticbeta Lactam AntibioticsAnti-Bacterial AgentsAntibodiesbeta-LactamsHumansFemaleProspective StudiesMaleIncidenceMiddle AgedAgedChinaAdultCohort StudiesHemoglobins

Stichwörter der Autor:innen

beta‐lactamsdrug‐induced hemolytic anemiapharmacovigilancesubclinical hemolysis

Substanzen

beta Lactam AntibioticsAnti-Bacterial AgentsAntibodiesHemoglobinsbeta-Lactams

Autor:innen und Institutionen

  • Department of Transfusion Medicine, Sichuan University West China Hospital, Chengdu, China.

ORCID-Profile: Li Wang

Zitieren

APA

Wang, L., Wang, L., Wei, Z., Huang, C., Qin, L., & Tan, B. (2026). Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70259

Vancouver

Wang L, Wang L, Wei Z, Huang C, Qin L, Tan B. Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70259

BibTeX
@article{Wang2026,
  author = {Wang, Li and Wang, Lixin and Wei, Zengzhen and Huang, Chunyan and Qin, Li and Tan, Bin},
  title = {Incidence and Clinical Significance of Drug‐Induced Antibodies and Hemolytic Anemia Associated With Beta‐Lactam Antibiotics: A Prospective Cohort Study},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2026},
  doi = {10.1002/pds.70259}
}
Kostenlos starten →